Wockhardt Ltd shares surged up to 20% on December 1, 2025

shares surged up to 20% on December 1, 2025, hitting a high of ₹1,473.70 after the US FDA formally accepted its New Drug Application (NDA) for Zaynich, a first-in-class antibiotic targeting complicated urinary tract infections (cUTIs) from multi-drug resistant gram-negative bacteria.